PubMed articles specifically about using GLP-1 receptor agonists for weight loss.

Vilsbøll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ. 2012;344:d7771. doi: 10.1136/bmj.d7771. PMID: 22236411.

Wadden TA, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes (Lond). 2013;37(11):1443-1451. doi: 10.1038/ijo.2013.120. PMID: 23852338.

Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11-22. doi: 10.1056/NEJMoa1411892. PMID: 26132939.

Davies MJ, Bergenstal R, Bode B, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE Diabetes randomized clinical trial. JAMA. 2015;314(7):687-699. doi: 10.1001/jama.2015.9676. PMID: 26301689.

Frias JP, Nauck MA, Van J, et al. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet. 2018;392(10160):2180-2193. doi: 10.1016/S0140-6736(18)32260-8. PMID: 30415907.

    These articles discuss the efficacy and safety of GLP-1 receptor agonists, such as liraglutide, for weight loss in individuals with and without type 2 diabetes. They provide evidence that GLP-1 receptor agonists can help to promote weight loss and improve metabolic parameters, such as blood sugar levels, in these populations.